Transcranial direct current stimulation (tDCS) has quietly moved from university research labs into clinical corridors – and increasingly into patients’ homes. As a radiology professional, you may already be seeing referrals that mention it, or reading MRI reports that document electrode-related scalp findings. Understanding the basics of tDCS, how it interacts with neuroimaging workflows, and what the latest devices look like will help you serve patients and collaborate more effectively with neurology colleagues.

What Is tDCS and Why Is It Relevant to Radiology?

Transcranial direct current stimulation is a non-invasive neuromodulation technique that delivers a low, constant electrical current – typically between 1 and 2 milliamps – through electrodes placed on the scalp. Unlike transcranial magnetic stimulation (TMS), it produces no loud clicks, no significant mechanical artifacts, and no absolute contraindication to subsequent MRI in most standard protocols.

The current passes through the skull and modulates the resting membrane potential of cortical neurons. Anodal stimulation (positive electrode) generally increases neuronal excitability, while cathodal stimulation decreases it. This targeted modulation is what makes tDCS attractive for treating conditions including major depressive disorder, chronic pain, post-stroke motor rehabilitation, and certain cognitive impairments.

For radiologists, the relevance is threefold:

1. Pre-imaging assessment: Patients using home tDCS devices may present for neuroimaging. Understanding the technology helps you identify any contraindications or protocol considerations.
2. Post-tDCS neuroimaging findings: fMRI and perfusion studies are increasingly used to validate tDCS effects. Radiologists interpreting these scans should be familiar with expected signal changes.
3. Incidental findings: Scalp erythema or electrode marks noted on positioning may prompt questions from clinical teams that a well-briefed radiologist can address.

MRI Safety Considerations in tDCS Patients

The good news is that modern consumer tDCS devices are entirely passive when not powered – there are no ferromagnetic components in the electrode assemblies of most leading devices. However, best practice is to confirm that electrodes and headsets have been removed before the patient enters the scanner room.

Key considerations include:

• Electrode gel residue: Saline or conductive gel used during tDCS sessions can remain on the scalp. While this poses no MRI safety risk, it may subtly affect surface coil coupling in high-field systems. Instruct patients to wash their scalp before MRI appointments where surface coils will be used.
• Headset components: Some newer combined tDCS/EEG headsets incorporate small electronic components. Always consult the device’s MRI compatibility documentation before proceeding. When in doubt, request the device manufacturer’s specifications.
• Research protocols: If a patient is enrolled in a tDCS clinical trial that includes concurrent or immediate post-stimulation fMRI, coordinate with the trial team on protocol sequencing. BOLD fMRI and perfusion changes from tDCS can persist for at least an hour after stimulation in many protocols, so timing relative to the last session matters.

Neuroimaging Findings Associated with tDCS

A growing body of fMRI literature documents the hemodynamic effects of tDCS. Radiologists interpreting research or clinical fMRI studies in this context should be aware of the following:

BOLD Signal Changes

Anodal tDCS over the primary motor cortex (M1) has consistently been shown to increase BOLD signal in the stimulated region during and immediately after stimulation. Cathodal stimulation produces the opposite effect. These changes are modest – typically within the range of normal task-related activation – but can confound activation maps if stimulation timing is not accounted for in the analysis model.

Cerebral Blood Flow

Arterial spin labeling (ASL) perfusion imaging has demonstrated increased regional cerebral blood flow under the anode in several studies. These perfusion changes mirror the excitability increases measured by TMS motor evoked potentials and return to baseline within approximately one hour. An ASL study ordered shortly after a tDCS session may therefore show focal hyperemia in a distribution that tracks electrode placement – a finding that should prompt clinical correlation rather than immediate concern.

Connectivity Alterations

Resting-state fMRI connectivity studies have shown that tDCS can transiently alter functional connectivity between stimulated regions and their network partners. For example, anodal stimulation over the dorsolateral prefrontal cortex (DLPFC) – the most common target in depression protocols – modulates connectivity within the default mode network. Radiologists reading resting-state reports should note whether recent neuromodulation has occurred, as it may influence network-level findings.

How Electrode Placement Maps to Neuroanatomy

Understanding the 10–20 EEG system used for tDCS electrode placement helps radiologists correlate stimulation targets with anatomical regions on imaging. Common clinical targets include:

When reviewing a structural MRI alongside a tDCS treatment record, this mapping allows you to correlate electrode targets with underlying anatomy – useful when patients present with new neurological symptoms and a history of home neurostimulation.

The Landscape of Consumer tDCS Devices

The past five years have seen a significant expansion in commercially available tDCS devices, ranging from medical-grade clinical systems to consumer-grade home-use headsets. Radiologists and neuroimaging teams benefit from familiarity with the device ecosystem, particularly as patients increasingly self-treat without formal clinical supervision.

Resources like tDCS Devices provide detailed comparative reviews of the leading devices on the market – covering specifications such as current output range, electrode configuration, companion app functionality, and safety certifications. Understanding the difference between an FDA-cleared medical device and a consumer wellness product is clinically meaningful: the former typically offers precise current control and traceable dosimetry, while the latter may not document stimulation parameters in a format usable for clinical correlation.

Key device categories include:

• Medical-grade clinical systems (e.g., Soterix Medical, Caputron ActivaDose): Designed for research and clinical settings, with precise current control, dosimetry logging, and FDA clearance in specific indications.
• CE-certified consumer devices (e.g., Flow tDCS Headset): Primarily marketed in the EU and UK for depression, featuring companion apps and structured treatment programs.
• General consumer neurostimulation headsets: A broad category with variable quality and documentation. These are the devices most likely to appear in a patient’s history without formal clinical involvement.

When a patient discloses tDCS use, asking which device they use and at what parameters (current level, session duration, electrode placement) provides the information needed to assess neuroimaging findings in context.

Practical Guidance for the Neuroimaging Team

Based on current evidence and device characteristics, the following practical recommendations apply to neuroimaging departments encountering tDCS-using patients:

Pre-scan intake forms should include a question about neuromodulation device use alongside existing questions about implanted devices and metal exposure. A simple addition – “Do you use any brain stimulation devices, including tDCS or neurostimulation headsets?” – is sufficient.

Timing of MRI relative to tDCS sessions matters for functional and perfusion studies. For structural MRI, timing is generally not a concern. For fMRI or ASL perfusion, a washout period of at least 90 minutes from the end of the last tDCS session is advisable to minimize residual hemodynamic effects.

Communication with referring clinicians is key when imaging findings might be attributable to recent tDCS. A brief note in the report – “Clinical correlation with recent neuromodulation history is recommended” – protects both the patient and the reporting radiologist.

Research environments running concurrent tDCS-fMRI protocols should develop site-specific standard operating procedures in collaboration with the physics and neuroradiology teams.

Looking Ahead: tDCS and Neuroimaging in the Coming Decade

The trajectory of tDCS research points toward increasingly personalized stimulation protocols guided by individual neuroimaging data. Computational models of current flow – derived from a patient’s own structural MRI – are already being used in research settings to optimize electrode placement and predict electric field distribution in cortical targets. In the coming years, this imaging-guided approach may become standard in clinical tDCS practice, placing neuroimaging at the center of treatment planning rather than at the periphery.

For radiology departments, this evolution represents both a clinical opportunity and a responsibility. The same MRI data used for diagnostic purposes could, with appropriate infrastructure and multidisciplinary collaboration, directly inform neurostimulation therapy. Radiologists who develop fluency in tDCS technology now will be well positioned to contribute meaningfully to that integrated model of care.

This article is intended for educational purposes for radiology and neuroimaging professionals. Clinical decisions regarding tDCS use should be made in consultation with qualified neurology and psychiatry teams.

Related posts:

Other Imaging Techniques in Dilated Cardiomyopathy Basic Echocardiography in Arrhythmogenic Right Ventricular Cardiomyopathy Ultrasound Cost With Insurance: What You’ll Really Pay Today How to Make Your Hospital a Better Place to Work: Proven Tips for Nursing Leaders Balancing AI Innovation in Radiology With Patient Privacy Rights CBCT In Dental Implant Planning: Radiographic Risk Assessment And Anatomical Considerations

Stay updated, free articles. Join our Telegram channel

Join